Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05570851 · ClinicalTrials.gov registry record · NA

Alcohol Cessation Among Head and Neck Cancer Survivors

A NA study of Head and Neck Cancer and Alcohol Use, Unspecified, sponsored by Northwell Health.

Active
Registry status
NA
Development phase
138
Enrollment target
1
Study location

NCT05570851 is a NA study of Head and Neck Cancer and Alcohol Use, Unspecified that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 138 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05570851, a NA study of Head and Neck Cancer and Alcohol Use, Unspecified, is active but no longer recruiting, sponsored by Northwell Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
138 participants
Enrollment target
1
Study location

Study Summary

Head-and-neck cancers (HNC) account for 4 percent of cancer diagnoses in the United States and for more than 66,000 annual cancer diagnoses. The prevalence rate of HNC among Veterans is 150% higher than the rate in the general population. Together with smoking, alcohol drinking is a major risk factor for HNC, responsible for approximately one-third of the cases worldwide. Overwhelming evidence from population-based studies show that alcohol drinking significantly increases the risk of recurrence of the primary HNC and of second primary malignancies, as well as negatively impacts HNC survivors' psychosocial health. Hence, several organizations (i.e., American Cancer Society, American Society of Clinical Oncology, and the World Cancer Research Fund) have issued guidelines recommending that individuals with HNC reduce or avoid alcohol altogether. Despite these recommendations, a substantial proportion of HNC survivors continue to use alcohol. The overall goal of the proposed research is to: 1. Adapt an existing evidence-based text message alcohol cessation intervention for HNC survivors in both civilian and VA settings (i.e., at two sites, Northwell Health and the Brooklyn VA Medical Center); and 2. Preliminarily evaluate, in a two-arm pilot RCT, the acceptability and preliminary efficacy of the intervention, as well as feasibility of conduct a future RCT. The investigators hypothesize that: * H1: The tailored text-message intervention will be 1) feasible to evaluate in a large-scale RCT, defined as achieving an enrollment rate of ≥70% in this pilot; and 2) acceptable to participants, defined as a score ≥4 on a 5-point Likert scale ranging from "not at all" to "extremely" acceptable. * H2: Compared to the control condition of alcohol assessment and feedback (AF), the tailored text messages will result in a 30% increase in cessation among survivors (assuming also a 20% increase in cessation in the AF arm).

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL Alcohol Cessation Text Messages

Study Locations (1)

New York

  • Feinstein Institutes for Medical Research - Manhasset

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2023-12-01
Est. Completion 2026-03-31
Phase NA

Sponsor

Northwell Health

370 total trials

What the Registry Record Tells You About NCT05570851

The ClinicalTrials.gov registry entry for NCT05570851 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT05570851 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05570851 about?

NCT05570851 is a clinical study titled "Alcohol Cessation Among Head and Neck Cancer Survivors". Head-and-neck cancers (HNC) account for 4 percent of cancer diagnoses in the United States and for more than 66,000 annual cancer diagnoses. The prevalence rate of HNC among Veterans is 150% higher than the rate in the general population. Together with smoking, alcohol drinking is a major risk facto...

What is the current status of trial NCT05570851?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 138 participants. The study started on 2023-12-01. Estimated completion is 2026-03-31.

What conditions does trial NCT05570851 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Alcohol Use, Unspecified.

What interventions are being tested in trial NCT05570851?

The interventions under investigation include: Usual Care (BEHAVIORAL), Alcohol Cessation Text Messages (BEHAVIORAL).

Who is sponsoring clinical trial NCT05570851?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05570851 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.